← Back to ADMAPortrait, one to two pages. Turn on “background graphics” in the print dialog to keep the table rules.

SPZCOADMA BIOLOGICS, INC. · ADMAData at close 2026-07-29

Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1368514 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote

Last $8.71Day −0.91%Mkt cap $2.0BP/E (FY) 14.5×1Y −52.3%Off 52W high −57.4%Vol (1Y) 54.3%

Price2023-07-31 → 2026-07-29

ADMA close: $4.2 on 2023-07-31 to $8.7 on 2026-07-29.

Daily closing price, split-adjusted to the current basis; 3y shown of 3,210 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.

At a glance

Fair value (model)$2.32

Implied upside−73.4%

Valuation confidenceLOW

Price impliesNEVER-OBSERVED · 42.0% growth

Short interest10.4% of sh out

Days to cover9.1d

13F net flow (QoQ)+3.85%

Top-10 13F concentration51.4%

Next report (est.)2026-08-05

Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.

Key fundamentalsFY 2025

P/E (FY)14.5×

Sales (TTM)$509.9M

Trailing returns

YTD−52.2%

1Y−52.3%

3Y+109.9%

5Y+441.0%

10Y+11.0%

Since incept. (ann.)+0.1%

Total return through 2026-07-29 · series begins 2013-10-17. Only the windows this history actually covers are shown.

Risk

Ann. volatility (1Y)54.3%

Ann. volatility (3Y)57.3%

Sharpe (1Y)−1.07

Sharpe (3Y)0.73

Max drawdown (1Y)−62.7%

Max drawdown (3Y)−69.0%

Beta (3Y vs SPY)1.33

Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.

Top institutional holders13F 2026-Q1

Manager	Shares	Value	% sh out	QoQ
BlackRock, Inc.	36.8M	$332M	15.89%	+1.4%
STATE STREET CORP	14.1M	$127M	6.08%	+3.6%
Capital Research Global Investors	11.2M	$101M	4.83%	+68.6%
VANGUARD CAPITAL MANAGEMENT LLC	10.3M	$93M	4.45%	new
VANGUARD PORTFOLIO MANAGEMENT LLC	8.9M	$80M	3.83%	new
Nuveen, LLC	6.1M	$55M	2.63%	+2.9%
GEODE CAPITAL MANAGEMENT, LLC	5.8M	$52M	2.51%	−0.1%
CITADEL ADVISORS LLC	5.8M	$52M	2.51%	+281.6%

Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.

Latest reported quarterslast report 2026-05-06

Period end	Reported	EPS	EPS YoY	Revenue	Rev YoY
2026-03-31	2026-05-06	$0.19	+72.7%	$114.5M	−0.3%
2025-12-31	2026-02-25	—	—	$139.2M	+18.4%
2025-09-30	2025-11-05	$0.15	+0.0%	$134.2M	+12.0%
2025-06-30	2025-08-06	$0.14	+7.7%	$122.0M	+13.8%

EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.

Segment mixFY2025 (ended Dec 2025)

ADMABio Manufacturing 97% · Plasma Collection Centers 3%

business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.

Basis & disclosures

End-of-day only. Every price on this sheet is a stored CLOSE — the last one is 2026-07-29. Nothing here is live, intraday or delayed-real-time, and the sheet does not update after it is printed.
Nothing is imputed. A figure that is not in the underlying filing or feed renders as “—”. We never fill a gap with an estimate, a peer median or a carried-forward value.
Mixed as-of dates by design. Prices are at the last close; fundamentals are at the latest reported fiscal period; 13F ownership is at the latest filed quarter (45+ days in arrears); short interest is the latest FINRA settlement. Each block states its own basis above.
Not investment advice. Model fair values, reverse-DCF grades and confidence labels are the output of published, disclosed methods on public filings — they are analysis, not a recommendation, a price target or a solicitation.
Fundamentals and ownership derive from SEC EDGAR (and equivalent foreign registers); prices from a licensed end-of-day vendor, shown under a neutral source label. Full methodology at spzco.com/methodology.